SCHEMBL5964602

SCHEMBL5964602

CN(Cc1ccc(-c2ccc(Br)cc2)o1)CC(O)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ ALDH1A1 P00352 2/20 0.44
▸ HSD17B10 Q99714 2/20 0.44
▸ RXFP1 Q9HBX9 2/20 0.44
▸ MAPT P10636 2/20 0.44
▸ NPSR1 Q6W5P4 2/20 0.44
▸ PKM P14618 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ TSHR P16473 1/20 0.44
▸ PPARG P37231 1/20 0.44
▸ NCOA2 Q15596 1/20 0.44
▸ NCOR2 Q9Y618 1/20 0.44
▸ CNR2 P34972 1/20 0.44
▸ KDM4E B2RXH2 3/20 0.43
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ AOC3 Q16853 2/20 0.41
▸ HTR1A P08908 1/20 0.41
▸ DRD2 P14416 1/20 0.41
▸ HTR2A P28223 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5963771 0.88 MEN1 (0.46) MEN1KMT2AALDH1A1HSD17B10MAPT
SCHEMBL5964615 0.78 PRMT1 (0.59) MEN1KMT2AALDH1A1RXFP1CNR2
SCHEMBL4341265 0.77 MEN1 (0.66) MEN1KMT2AALDH1A1TSHRCNR2
SCHEMBL4344968 0.77 MEN1 (0.66) MEN1KMT2AALDH1A1TSHRCNR2
SCHEMBL4352641 0.77 MEN1 (0.66) MEN1KMT2AALDH1A1TSHRCNR2
SCHEMBL5964114 0.75 CNR2 (0.64) MEN1KMT2AALDH1A1MAPTNPSR1
SCHEMBL25159497 0.74 MEN1 (0.62) MEN1KMT2ACNR2KDM4ESMN1; SMN2
SCHEMBL10431857 0.74 MEN1 (0.62) MEN1KMT2ACNR2KDM4ESMN1; SMN2
SCHEMBL6396582 0.74 ALDH1A1 (0.53) MEN1KMT2AALDH1A1HSD17B10RXFP1
SCHEMBL5964603 0.73 ALDH1A1 (0.54) ALDH1A1HSD17B10RXFP1MAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060052315-A1 Cb 1/cb 2 receptor ligands and their use in the treatment of pain ASTRAZENECA AB (SE) 2006-03-09 — — US claimed
EP-1594856-A1 CB 1/CB 2 RECEPTOR LIGANDS AND THEIR USE IN THE TREATMENT OF PAIN AstraZeneca AB (SE) 2005-11-16 — — EP claimed
WO-2004060882-A1 CB 1/CB 2 RECEPTOR LIGANDS AND THEIR USE IN THE TREATMENT OF PAIN ASTRAZENECA AB (SE) 2004-07-22 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052315-A1 Cb 1/cb 2 receptor ligands and their use in the treatment of pain CNR1, CNR2, OPRL1 MEN1 4443/4885KMT2A 2160/4885ALDH1A1 806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback